Evidence map›Paper›PMID 36334594›Full record

ArticleCell reports. Medicine2022

Enhanced TLR3 responsiveness in hepatitis C virus resistant women from the Irish anti-D cohort.

Jamie A Sugrue, Céline Posseme, Ziyang Tan, Christian Pou, Bruno Charbit, Vincent Bondet, Nollaig M Bourke, Petter Brodin, Darragh Duffy, Cliona O'Farrelly

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Jamie A SugrueSchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Céline PossemeTranslational Immunology Unit, Institut Pasteur, Paris, France.
Ziyang TanScience for Life Laboratory, Department of Women's and Children Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Christian PouScience for Life Laboratory, Department of Women's and Children Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Bruno CharbitCytometry and Biomarkers UTechS, CRT, Institut Pasteur, Paris, France.
Vincent BondetTranslational Immunology Unit, Institut Pasteur, Paris, France.
Nollaig M BourkeDiscipline of Medical Gerontology, School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland.
Petter BrodinScience for Life Laboratory, Department of Women's and Children Health, Karolinska Institutet, 17165 Stockholm, Sweden.
Darragh DuffyTranslational Immunology Unit, Institut Pasteur, Paris, France; Cytometry and Biomarkers UTechS, CRT, Institut Pasteur, Paris, France.
Cliona O'FarrellySchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland; School of Medicine, Trinity College Dublin, Dublin, Ireland. Electronic address: ofarrecl@tcd.ie.
Institut Pasteur · FRScience for Life Laboratory · SETrinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural resistance to infection is an overlooked outcome after hepatitis C virus (HCV) exposure. Between 1977 and 1979, 1,200 Rhesus D-negative Irish women were exposed to HCV-contaminated anti-D immunoglobulin. Here, we investigate why some individuals appear to resist infection despite exposure (exposed seronegative [ESN]). We screen HCV-resistant and -susceptible donors for anti-HCV adaptive immune responses using ELISpots and VirScan to profile antibodies against all know human viruses. We perform standardized ex vivo whole blood stimulation (TruCulture) assays with antiviral ligands and assess antiviral responses using NanoString transcriptomics and Luminex proteomics. We describe an enhanced TLR3-type I interferon response in ESNs compared with seropositive women. We also identify increased inflammatory cytokine production in response to polyIC in ESNs compared with seropositive women. These enhanced responses may have contributed to innate immune protection against HCV infection in our cohort.

Indexed as

HepacivirusHepatitis CAntiviral AgentsFemaleHumansRho(D) Immune GlobulinToll-Like Receptor 3Antiviral AgentsRHO(D) antibodyRho(D) Immune GlobulinTLR3 protein, humanToll-Like Receptor 3exposed seronegativehepatitis Cimmune variationinnate immunitysystems immunologytype I interferonviral resistance

Identifiers

PMID36334594
PMCPMC9729829
OpenAlexW4308207442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.